Magnesium sulfate versus placebo for paroxysmal atrial fibrillation: A randomized clinical trial

Academic Emergency Medicine

Volumn 16, Issue 4, 2009, Pages 295-300

  Chu, Kevin ^a,b,c   Evans, Rhona ^a   Emerson, Gregory ^a   Greenslade, Jaimi ^a   Brown, Anthony ^a,b,c  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b Emergency Medicine Evaluation and Research Group Queensland (EMERG Q)   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Atrial fibrillation; Magnesium sulfate; Randomized clinical trial

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; CHLORVESCENT; MAGNESIUM SULFATE; PLACEBO; POTASSIUM BICARBONATE; POTASSIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECHOCARDIOGRAPHY; EMERGENCY PATIENT; EMERGENCY WARD; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE; HEART RATE; HEART RHYTHM; HUMAN; HYPOTENSION; MALE; ONSET AGE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEART RATE; HOSPITALS, UNIVERSITY; HUMANS; LINEAR MODELS; MAGNESIUM SULFATE; MALE; MIDDLE AGED; PLACEBOS; QUEENSLAND; SODIUM CHLORIDE; TIME FACTORS; YOUNG ADULT;

EID: 65249154189     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2009.00360.x     Document Type: Article

References (12)

1. Onalan O, Crystal E, Daoulah A, Lau C, Crystal A, Lashevsky I. Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. Am J Cardiol. 2007; 99:1726-32.
2. Fuster V, Ryden LE, Cannom DS, et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114:e257-354.
3. Hays JV, Gilman JK, Rubal BJ. Effect of magnesium sulfate on ventricular rate control in atrial fibrillation. Ann Emerg Med. 1994; 24:61-4.
4. Brodsky MA, Orlov MV, Capparelli EV, et al. Magnesium therapy in new-onset atrial fibrillation. Am J Cardiol. 1994; 73:1227-9.
5. Walker S, Taylor J, Harrod R. The acute effects of magnesium in atrial fibrillation and flutter with a rapid ventricular rate. Emerg Med [Fremantle]. 1996; 8:207-13.
6. Joshi PP, Deshmukh PK, Salkar RG. Efficacy of intravenous magnesium sulphate in supraventricu- lar tachyarrhythmias. J Assoc Physicians India. 1995; 43:529-31.
7. Gullestad L, Birkeland K, Molstad P, Hoyer MM, Vanberg P, Kjekshus J. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clin Cardiol. 1993; 16:429-34.
8. Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol. 2001; 79:287-91.
9. Bryk AS, Raudenbush SW. Hierarchical Linear Models: Applications and Data Analysis Methods. Thousand Oaks, CA: Sage Publications, 1992.
10. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001; 357:1191-4.
11. Davey MJ, Teubner D. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. Ann Emerg Med. 2005; 45:347-53.
12. Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P. Parenteral magnesium sul- fate versus amiodarone in the therapy of atrial tach- yarrhythmias: a prospective, randomized study. Crit Care Med. 1995; 23:1816-24.